Form 4: Sera Prognostics Director Kim Kamdar Granted New Equity Awards

Sera Prognostics, Inc. Director Kim P. Kamdar was granted 15,596 restricted stock units and 25,000 stock options as part of her compensation, vesting monthly over one year starting June 5, 2025.

Summary

• Kim P. Kamdar, a Director of Sera Prognostics, Inc. (SERA), acquired 15,596 shares of Class A Common Stock in the form of Restricted Stock Units (RSUs) on June 5, 2025.
• These RSUs were granted at a price of $0 and will vest monthly over one year, with 1/12 of the original grant vesting each month, commencing June 5, 2025, contingent on her continued service.
• Additionally, Ms. Kamdar was granted 25,000 stock options to purchase Class A Common Stock at an exercise price of $1.6 per share on June 5, 2025.
• These stock options were granted at a price of $0 and also vest monthly over one year, with 1/12 of the original grant vesting each month, commencing June 5, 2025.
• The stock options were granted under Sera Prognostics, Inc.'s Non-Employee Director Compensation Policy and its 2021 Equity Incentive Plan, and expire on June 5, 2035.
• Following these transactions, Ms. Kamdar beneficially owns 29,342 shares of Class A Common Stock and 25,000 stock options.

Sentiment

Score: 7

Explanation: The document reports a routine equity compensation grant to a director, which is a positive for aligning interests but does not contain significant new operational or financial news to dramatically shift sentiment. It's a standard, expected disclosure.

Positives

• The grant of equity awards to a director aligns the director's interests with those of shareholders, incentivizing long-term performance.
• The vesting schedule over one year encourages continued service and commitment from the director.

Future Outlook

The vesting schedules for both the RSUs and stock options indicate a future commitment from the director, with monthly vesting installments over one year from June 5, 2025, contingent on continued service.

Industry Context

This Form 4 filing reflects a routine equity compensation grant to a non-employee director, a common practice across industries, particularly in the biotechnology or healthcare diagnostics sector where Sera Prognostics operates. Such grants are designed to align director incentives with long-term shareholder value creation, a standard corporate governance practice.

Comparison to Industry Standards

• The grant of restricted stock units and stock options to a non-employee director is a standard compensation practice in the U.S. public company landscape, particularly for growth-oriented companies in the biotech and diagnostics space.
• The vesting schedule of one year with monthly installments is also common, aiming to retain directors and align their interests with sustained company performance.
• While specific comparable companies (e.g., Natera, Inc., Veracyte, Inc., Exact Sciences Corp.) would have their own compensation structures, the general approach of equity-based compensation for directors is a widely adopted benchmark.

Corporate Governance

Related Party Transactions

• Grant of 15,596 Restricted Stock Units and 25,000 stock options to Kim P. Kamdar, a Director of Sera Prognostics, Inc., as part of her compensation.

Stakeholder Impact

• Shareholders: The equity grants align the director's interests with shareholders, potentially leading to better long-term performance. Dilution from the issuance of shares upon RSU vesting and option exercise is a minor consideration.

Next Steps

• Continued monthly vesting of 1/12 of the granted RSUs and stock options for one year, starting June 5, 2025, subject to the director's continued service.

Key Dates

Recommendation

Keywords

Sera Prognostics, SERA, Form 4, Insider Transaction, Equity Grant, Restricted Stock Units, RSU, Stock Options, Director Compensation, Kim P. Kamdar, Beneficial Ownership